Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
Hosted on MSN4d
Denmark's trump card against US's Greenland threat: Weight-loss drug
Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there ...
Why Trump’s Bid to Take Greenland Would Cause an Ozempic War
Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...
A cautionary tale that Europe can’t afford to ignore
It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...